Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer

참고문헌 (9)

1. McDermott J, "Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer", Drugs Today (Barc), 51, pp.7~20 (2015)[DOI]
2. Vallet H, "Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma", Ann Oncol, 27, pp.1352~1353 (2016)[DOI]
3. Zimmer L, "Neurological, respiratory, musculoskeletal, cardiac and ocular sideeffects of anti-PD-1 therapy", Eur J Cancer, 60, pp.210~225 (2016)[DOI]
4. Lau KH, "Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab", Muscle Nerve, 54, pp.157~161 (2016)[DOI]
5. Zhu J, "Myasthenia gravis exacerbation associated with pembrolizumab", Muscle Nerve, 54, pp.506~507 (2016)[DOI]
6. Gonzalez NL, "Myasthenia triggered by immune checkpoint inhibitors: new case and literature review", Neuromuscul Disord, 27, pp.266~268 (2017)[DOI]
7. Haddox CL, "Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm", Ann Oncol, 28, pp.673~675 (2017)
8. March KL, "Pembrolizumab-induced myasthenia gravis: a fatal case report", J Oncol Pharm Pract, 1, pp.10781 55216687389~ (2017)
9. Makarious D, "Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors", Eur J Cancer, 82, pp.128~136 (2017)[DOI]